Sparsha Pharma International Private Limited has a strong R&D Unit with a good number of research staff continuously working on designing and developing the various types of Transdermal patches. This R&D facility is recognized by the Department of Scientific and Industrial Research (DSIR) which is the part of the Ministry of Science and Technology, Government of India.
Sparsha Pharma International Private Limited's R&D Unit develops innovative transdermal patch technologies with a dedicated team of researchers. The Department of Scientific and Industrial Research (DSIR), a key agency under India's Ministry of Science and Technology, recognises the unit's outstanding capabilities.
This esteemed award shows our dedication to scientific inquiry and innovation. Our team works to improve medication delivery efficacy, explore new formulations, and develop next-generation patches to meet complex therapeutic needs and extend treatment options for patients globally.
OUR UNIQUE CAPABILITIES
Sparsha Pharma International Private Limited proudly stands as India’s pioneering and most established player in the transdermal drug delivery space, driven by a deep commitment to innovation, quality, and therapeutic advancement.
With a cumulative R&D expertise spanning over 30 years, and more than 17 years of focused experience in matrix-based transdermal patch development, our scientific leadership continues to set industry benchmarks. This rich foundation of specialized knowledge enables us to engineer highly effective, patient-compliant transdermal systems tailored to a variety of therapeutic needs.
Our proven operational track record includes the annual production and distribution of over 10 million patches, successfully catering to both domestic and global markets. This consistent supply performance underscores our manufacturing strength, regulatory compliance, and trusted partnerships across continents.
One of the most critical challenges in transdermal technology—maintaining long-lasting adhesion under high-temperature and high-humidity conditions—has been successfully overcome by our team. In tropical climates like India, where many global formulations fail to adhere effectively, Sparsha Pharma has developed proprietary solutions to ensure reliable adhesion throughout the patch’s wear time. This accomplishment highlights not only our formulation excellence, but also our ability to deliver clinically reliable products across geographies and climate conditions.
If you would like to know more about our specific capabilities, please contact us at Sparsha Pharma International Pvt. Ltd. , #8-2-408, 4th Floor, Meenakshi House, Road Number 7, Banjara Hills, Hyderabad, Telangana State 500034. India.
Tel: +91-40-23352580, Email: info@sparsha.com, website: www.sparsha.com
At Sparsha Pharma, our R&D department is relentlessly focused on developing innovative and advanced drug delivery solutions. With a strong emphasis on Central Nervous System (CNS) therapies, we are actively engaged in formulating next-generation transdermal patches that enhance patient compliance and therapeutic outcomes.
Our ongoing research pipeline reflects our commitment to continuous innovation—expanding transdermal technology across diverse therapeutic areas through scientific excellence, cutting-edge formulation design, and a patient-centric approach.
